Navigation Links
Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
Date:9/4/2007

n of relapsed patients who receive other second-line chemotherapy," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "These results are promising because patients with platinum-resistant and -refractory small cell lung cancer have very limited treatment options. They typically experience rapid disease progression and low overall survival following treatment with existing chemotherapies, which have significant toxicities."

The updated picoplatin Phase 2 data were presented during a poster discussion session at the International Association for the Study of Lung Cancer's (IASLC) 12th World Conference on Lung Cancer in Seoul, Korea.

Additional Phase 2 Study Findings

In addition to the overall and one-year survival findings, the updated analysis of results from the open-label, multi-center Phase 2 trial showed that the disease control rate was 48.1 percent in the 77 evaluable patients. This is similar to that observed with currently available treatments, but with a more manageable side effect profile and less frequent administration. At the time of the updated analysis, 63 patients had died from disease progression. The most common side effects were hematologic and included thrombocytopenia, anemia and neutropenia. No grade 3 or 4 neurotoxicity or nephrotoxicity and no treatment-related deaths occurred.

Pivotal Phase 3 SPEAR Trial Design

Poniard's ongoing international, multi-center, randomized, controlled SPEAR trial is comparing picoplatin plus best supportive care to best supportive care alone to evaluate the efficacy of picoplatin after relapse. Best supportive care includes care and treatment to optimize the comfort of patients and their ability to function, as well as to minimize the side effects of palliative cancer treatments. The primary efficacy endpoint is overall survival, with overall response rates, progression-free survival and disease control also being evaluated. The trial, which is enrolling patients who are refract
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015  Chiasma, Inc. (NASDAQ: ... octreotide capsules for the orphan condition acromegaly, today ... June 30, 2015 and provided a corporate update. ... a transformative time for Chiasma, as we successfully ... that our first New Drug Application (NDA) has ...
(Date:8/31/2015)... 2015 A new Transparency ... monitoring and diagnostic devices market stood at US$3.7 ... a value of approximately US$7.0 billion in 2019, ... and 2019. The title of the report is ... Monitors, Event Monitors, Cardiovascular Diagnostic Catheters, Implantable Loop ...
(Date:8/31/2015)... YORK , Aug. 31, 2015  Dipexium Pharmaceuticals, ... focused on the development and commercialization of Locilex® (pexiganan ... today announced plans to participate in four investor conferences ... 2, 2015 at the Sidoti & Company, LLC Emerging ... . David P. Luci , President & ...
Breaking Medicine Technology:Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 2Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 3Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 4Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 5Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 6Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 7Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 8Chiasma Reports Second Quarter 2015 Financial Results and Recent Business Highlights 9Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 4Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 5Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3
... announces the appointment of Susan C. Stansfield, PhD ... Development. In this position, Dr. Stansfield will have ... clinical trial management services provided to the biopharmaceutical ... proven leadership skills will be pivotal in enhancing ...
... Reportlinker.com announces that a new market research ... E7: The Outlook for Pharmaceuticals to ... The emerging E7 countries represent the ... these countries is huge: they have a ...
Cached Medicine Technology:Premier Research Names Susan Stansfield, PhD Executive VP, Clinical Development 2E7: The Outlook for Pharmaceuticals to 2012 2E7: The Outlook for Pharmaceuticals to 2012 3E7: The Outlook for Pharmaceuticals to 2012 4E7: The Outlook for Pharmaceuticals to 2012 5
(Date:9/1/2015)... CINCINNATI, OHIO (PRWEB) , ... September 01, 2015 , ... ... US today at JourneyLite of Cincinnati. In the last month the FDA has ... ReShape Duo ™. These procedures represent the first incisionless, reversible, weight loss ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... a next-generation customer communications archiving solution integrated with Alfresco‘s enterprise content management ... and helps organizations save millions of dollars in printing costs by digitizing ...
(Date:9/1/2015)... ... 01, 2015 , ... Award-winning adult film director and gender ... of female beauty, women’s emotions, fertility, female violence and sexual assault. She explores ... relationships with other men, documenting how the power balance between men and women ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Anthony J. ... the Super Lawyers 2015 for his third consecutive year in a row. Through ... accomplishments of helping people. , Born in Niagara Falls, New York, Tantillo is a ...
(Date:9/1/2015)... ... ... A new episode of “Voices In America”, hosted by famous actor and voice ... There are over 100 different types of arthritis. One of the most popular is ... to shed light on this important topic. , Anyone who is nearing their golden ...
Breaking Medicine News(10 mins):Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 2Health News:Introducing Next-Generation Archiving Solution PRO Archiver for Alfresco® 3Health News:Female Porn Director Explains Male Insecurities about Women in a New Book 2
... class as a child can turn people off fitness for ... Strean, a professor in the U of A,s Faculty of ... physical activity can be determined by either a good or ... coach or instructor. For example, negative experiences may come from ...
... the speech acquisition process in toddlers who have undergone cochlear ... Kerem of the University of Haifa. The study was carried ... in Denmark (supervised by Prof. Tony Wigram) and presented at ... Haifa. Some infants who are born with impaired hearing ...
... patients are partially protected by the influenza vaccine 6-10 ... while the flu vaccine is safe, it is ineffective ... rituximab treatment. Previous influenza vaccination in rituximab-treated patients ... to influenza strains. RA activity was not influenced ...
... Minnesota Medical School discovered that light from an ultraviolet ... epilepsy model. During the study, UV light released ... amino butanoic acid (BC204). GABA then decreased the abnormal ... Results of this study have considerable potential in ...
... -- The National Endowment for Humanities (NEH) has awarded a ... of Public Health at Columbia University,s Mailman School of Public ... help extend the Center,s intellectual mission to bring the ... facing public health through knowledge of its political, social cultural, ...
... SODA project has created a service-oriented ecosystem for ... software components in even low-cost devices in the ... of device to communicate using the same language ... will be in a wide range of applications ...
Cached Medicine News:Health News:Music therapy can assist toddlers' communication rehabilitation process 2Health News:Efficacy of flu vaccine drastically reduced for RA patients treated with rituximab 2Health News:UV LED therapy shows promising results in preventing focal seizures 2Health News:NEH grant to Center for History and Ethics of Public Health at Columbia's Mailman School 2Health News:Service-oriented ecosystem enables low cost devices to form interactive 'web of objects' 2Health News:Service-oriented ecosystem enables low cost devices to form interactive 'web of objects' 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: